{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:44:29Z","timestamp":1771598669266,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/rlu.0000000000000628","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T14:07:07Z","timestamp":1419948427000},"page":"123-127","source":"Crossref","is-referenced-by-count":45,"title":["Is There a Role for Peptide Receptor Radionuclide Therapy in Medullary Thyroid Cancer?"],"prefix":"10.1097","volume":"40","author":[{"given":"Fernanda","family":"Vaisman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Henrique","family":"Rosado de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia Paiva Proen\u00e7a Lobo","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Barretto","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cencita H.N.","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Alves","family":"Bulzico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"de Carvalho Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vilhena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Vaisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Corbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210204","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1043-2760(97)00168-9","article-title":"Somatostatin receptors.","volume":"8","author":"Patel","year":"1997","journal-title":"Trends Endocrinol Metab"},{"key":"R2-5-20210204","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s002590050269","article-title":"Somatostatin receptor imaging in intracranial tumours.","volume":"25","author":"Schmidt","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"R3-5-20210204","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"R4-5-20210204","first-page":"71","article-title":"Changing paradigms with molecular imaging of neuroendocrine tumors.","volume":"14","author":"Hofman","year":"2012","journal-title":"Discov Med"},{"key":"R5-5-20210204","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/A:1014972520302","article-title":"True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5.","volume":"72","author":"Schulz","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"R6-5-20210204","first-page":"1413","article-title":"In vivo somatostatin receptor imaging in medullary thyroid carcinoma.","volume":"76","author":"Kwekkeboom","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-5-20210204","first-page":"543","article-title":"Somatostatin receptor scintigraphy in medullary thyroid carcinoma.","volume":"84","author":"Tisell","year":"1997","journal-title":"Br J Surg"},{"key":"R8-5-20210204","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog 177 Lu-DOTA 0,Tyr3octreotate: toxicity, efficacy, and survival.","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R9-5-20210204","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2265.2001.01175.x","article-title":"Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.","volume":"54","author":"Papotti","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R10-5-20210204","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"American Thyroid Association Guidelines Task Force Medullary thyroid cancer: management guidelines of the American Thyroid Association.","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"R11-5-20210204","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","article-title":"Response to 90Yttrium-DOTA-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.","volume":"13","author":"Iten","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R12-5-20210204","first-page":"143","article-title":"Traducao para a lingua portuguesa e validacao do questionario generico de avaliacao de qualidade de vida SF-36 (Brasil SF-36).","volume":"39","author":"Ciconelli","year":"1999","journal-title":"Rev Bras Reumatol"},{"key":"R13-5-20210204","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2967\/jnmt.111.098277","article-title":"The SNM practice guideline for somatostatin receptor scintigraphy 2.0.","volume":"39","author":"Balon","year":"2011","journal-title":"J Nucl Med Technol"},{"key":"R14-5-20210204","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00259-010-1473-6","article-title":"111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.","volume":"37","author":"Bombardieri","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-5-20210204","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-5-20210204","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R17-5-20210204","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/00003072-200108000-00004","article-title":"Comparison of In-111 octreotide and Tc-99 m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery.","volume":"26","author":"Arslan","year":"2001","journal-title":"Clin Nucl Med"},{"key":"R18-5-20210204","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopha.2007.07.011","article-title":"Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.","volume":"62","author":"Rufini","year":"2008","journal-title":"Biomed Pharmacother"},{"key":"R19-5-20210204","doi-asserted-by":"crossref","first-page":"E207","DOI":"10.1210\/jc.2011-2766","article-title":"(111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents.","volume":"97","author":"Lodish","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-5-20210204","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00423-013-1086-1","article-title":"Routine preoperative (111)In-octreotide scintigraphy in patients with medullary thyroid cancer.","volume":"398","author":"Dahlberg","year":"2013","journal-title":"Langenbecks Arch Surg"},{"key":"R21-5-20210204","doi-asserted-by":"crossref","first-page":"448","DOI":"10.7150\/thno.3931","article-title":"Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs).","volume":"2","author":"Oberg","year":"2012","journal-title":"Theranostics"},{"key":"R22-5-20210204","first-page":"92","article-title":"Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.","volume":"54","author":"Gabriel","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R23-5-20210204","first-page":"39","article-title":"Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.","volume":"4","author":"Budiawan","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"R24-5-20210204","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/thy.2013.0225","article-title":"Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.","volume":"24","author":"Versari","year":"2014","journal-title":"Thyroid"},{"key":"R25-5-20210204","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.2004.10.016","article-title":"Quality of life in patients with gastroenteropancreatic tumors treated with 177Lu-DOTA0,Tyr3octreotate.","volume":"22","author":"Teunissen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R26-5-20210204","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/1450-1147.89779","article-title":"Improved quality of life in patients treated with Peptide radionuclides.","volume":"10","author":"Traub-Weidinger","year":"2011","journal-title":"World J Nucl Med"},{"key":"R28-5-20210204","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"R29-5-20210204","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer.","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000000628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:10:19Z","timestamp":1620972619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201502000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000000628","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}